Wednesday , 4 December 2024
Home Neurodegenerative Disease

Neurodegenerative Disease

Amylyx Pharmaceuticals
Healthcare

ALS Drug Relyvrio Withdrawn Due to Ineffectiveness

Amylyx Pharmaceuticals has decided to withdraw its ALS drug Relyvrio from the market following disappointing results from a phase III trial. The drug,...